Literature DB >> 7579410

Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin.

S Barillé1, M Collette, R Bataille, M Amiot.   

Abstract

Previous studies have shown that bone marrow, especially the bone microenvironment, may play an important role in the pathogenesis of multiple myeloma (MM). To elucidate the relationship between myeloma cells and bone cells, mainly osteoblasts, we have established a coculture system between two interleukin-6 (IL-6)-dependent myeloma cell lines, XG1 and XG6, and the osteosarcoma cell lines Saos-2 and MG63. Both osteosarcoma cell lines have retained major functions of normal osteoblasts; principally, the capacity to produce hematopoietic growth factors (including IL-6) and osteocalcin, a noncollagenic protein essential in the bone formation process. Because IL-6 is a critical growth factor in MM, we have examined the IL-6 osteoblastic cell production in our coculture system. XG1 cells strongly upregulate IL-6 production by MG63 and Saos-2 cells. Of major interest, the triggering of IL-6 is totally dependent on the physical contact between myeloma cells and osteoblastic cells, contact that is partly mediated by CD44, CD56, and fibronectin interactions. Osteocalcin production by MG63 and Saos-2 cells has previously been shown to be dependent on 1,25-(OH)2D3. We demonstrate that XG1 and XG6 cells reduced the amount of osteocalcin in MG63 coculture cell supernatants, a reduction that is partly mediated by a soluble factor and by cell-to-cell contact. Notably, whereas one of the myeloma cell lines, XG6, has lost its capacity to stimulate IL-6 production by osteoblastic cell lines, both XG1 and XG6 cell lines remain able to reduce the osteocalcin amount, indicating that IL-6 and osteocalcin levels are regulated by two different pathways. In conclusion, these data strongly support the concept that the bone microenvironment is directly modified by contact with myeloma cells and are consistent with the characteristics observed in vivo in patients with MM patients, ie, abnormally high IL-6 and low osteocalcin levels, respectively.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579410

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Advances in the understanding of myeloma bone disease and tumour growth.

Authors:  Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2010-03-11       Impact factor: 6.998

Review 2.  Proteasome inhibitors and bone disease.

Authors:  Ya-Wei Qiang; Christoph J Heuck; John D Shaughnessy; Bart Barlogie; Joshua Epstein
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

3.  Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: similarity to estrogen deficiency.

Authors:  C Miyaura; Y Onoe; M Inada; K Maki; K Ikuta; M Ito; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin.

Authors:  Abdullah Karadag; Min Zhou; Peter I Croucher
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

5.  MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Authors:  Sonia Vallet; Noopur Raje; Kenji Ishitsuka; Teru Hideshima; Klaus Podar; Shweta Chhetri; Samantha Pozzi; Iris Breitkreutz; Tanyel Kiziltepe; Hiroshi Yasui; Enrique M Ocio; Norihiko Shiraishi; Janice Jin; Yutaka Okawa; Hiroshi Ikeda; Siddhartha Mukherjee; Nileshwari Vaghela; Diana Cirstea; Marco Ladetto; Mario Boccadoro; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113

6.  Role of decorin in the antimyeloma effects of osteoblasts.

Authors:  Xin Li; Angela Pennisi; Shmuel Yaccoby
Journal:  Blood       Date:  2008-04-24       Impact factor: 22.113

Review 7.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

8.  Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.

Authors:  Jeena Joseph; Yusuke Shiozawa; Younghun Jung; Jin Koo Kim; Elisabeth Pedersen; Anjali Mishra; Janet Linn Zalucha; Jingcheng Wang; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Mol Cancer Res       Date:  2012-01-12       Impact factor: 5.852

9.  Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.

Authors:  Xin Li; Wen Ling; Sharmin Khan; Shmuel Yaccoby
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

10.  Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.

Authors:  Wenjie He; Amitabha Mazumder; Tuere Wilder; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-05-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.